Lupin gets USFDA nod for generic contraceptive tablets
New Delhi: Drug major Lupin said it has received approval from the US health regulator to market its Tydemy tablets, used to prevent pregnancy, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Tydemy, which is a generic version of Bayer HealthCare Pharmaceuticals' Safyral Tablets, Lupin said in a statement.
Tydemy is indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception.
As per IMS MAT data, the product had annual sales of around USD 22.9 million in the US.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd